Ricardo Villalobos V (@Rick_Villalobos) header
Ricardo Villalobos V (@Rick_Villalobos) profile picture
México
Joined April 2010
Photo by Ricardo Villalobos V (@Rick_Villalobos)Photo by Ricardo Villalobos V (@Rick_Villalobos)Photo by Ricardo Villalobos V (@Rick_Villalobos)Photo by Ricardo Villalobos V (@Rick_Villalobos)Photo by Ricardo Villalobos V (@Rick_Villalobos)Photo by Ricardo Villalobos V (@Rick_Villalobos)Photo by Ricardo Villalobos V (@Rick_Villalobos)Photo by Ricardo Villalobos V (@Rick_Villalobos)Photo by Ricardo Villalobos V (@Rick_Villalobos)Photo by Ricardo Villalobos V (@Rick_Villalobos)
Ricardo Villalobos V retweeted
List of 12 Approvals given in breast cancer by @usfda from 1st May 2026 till 16 th November 2026. For quick summary. #BCSM #OncoWisdom @DrUddiGoswami @dr_yakupergun @OncBrothers
18
2
43
4,158
Ricardo Villalobos V retweeted
Based on evERA trial, Giredestrant (oral SERD) + everolimus is now @FDA ✅ for HR+ mESR1 #breastcancer HR+ after CDK4/6i + ET: - ⬆️ PFS2: 19.02mos vs. 13.7mos (HR: 0.69) - Improved chemo-free survival: 11.1mos vs. 7.9 mos (HR: 0.61) - More options in mESR1 #OncTwitter #bcsm
Exciting news in breast oncology! FDA approves giredestrant + everolimus for ESR1-mutated, ER+/HER2− advanced breast cancer. #bcsm @ASCO @muschollings @OncBrothers The phase III evERA trial showed impressive PFS improvement: 10 vs 5.5 months (HR 0.38). fda.gov/drugs/cancer-approva…
14
1
27
2,221
Ricardo Villalobos V retweeted
Important phase 3 trial to be presented at #SABCS26 Most patients with stage II-III TNBC today are treated with the KEYNOTE-522 regimen, a highly effective, yet highly toxic 5 drug regimen. No biomarkers, no precision medicine, just size: if the tumor is larger than 20 mm, the full regimen is unleashed. Thanks to the inclusion of pembro in the neoadjuvant regimen, 1 out of 10 women with TNBC will be spared a disease recurrence. Which is a dramatic benefit. The other 9, though, will experience irTox with no benefit. If S1418 is positive, one could envision a selected group of patients receiving chemo alone, which could be rescued with pembro/chemo in case of residual disease. If the trial is negative, though, this would be one more confirmation that it is critical to have the tumor in place in order to unleash the full benefit of immune checkpoint inhibition. And that we will need to figure out other, better ways, to tailor preoperative treatment for our patients. Such as biomarkers. #SABCS26 will be yet one more major conference without the TILs analysis of KEYNOTE-522 in its program. Crossing fingers for #ASCO27. @Merck
The phase III SWOG S1418/NRG BR006 trial studies pembrolizumab after surgery for patients whose triple-negative breast cancer remained after preoperative chemotherapy. Lajos Pusztai, MD, DPhil, presents Dec. 9 at #SABCS26. Be part of what comes next: bit.ly/4zVrJXC
1
15
2
66
4,828
Ricardo Villalobos V retweeted
Everolimus-associated stomatitis: a practical guide to prophylaxis.
🚨 Great news! FDA approves giredestrant + everolimus for ESR1-mutated ER+/HER2− aBC Watch out for everolimus-related stomatitis! Don’t forget dexamethasone mouthwash. Perhaps 7.5 mg of everolimus would be a better option, as in ELEVATE and ADALE...
12
44
2,452
Ricardo Villalobos V retweeted
🚨 DOUBLING median survival in advanced NSCLC! 5-year EMPOWER-Lung 3 update in ESMO Open 🔥 In patients with PD-L1 ≥1%, cemiplimab + chemotherapy delivers durable survival benefit. 📊 Key results (n=327): 🔹 Median OS: 24.0 vs 12.1 months (HR 0.54) 🔹 5-year OS: 23.5% vs 8.2% 🔹 Median PFS: 8.3 vs 5.5 months (HR 0.50) 🔹 ORR: 48.4% vs 22.7% 🔬 Benefit by PD-L1 expression: * PD-L1 1–49%: OS HR 0.46 * PD-L1 ≥50%: OS HR 0.63 ⚠️ Grade ≥3 adverse events: 48.8% vs 27.5%. 💡 Verdict: Cemiplimab + chemotherapy demonstrates sustained survival benefit at 5 years across PD-L1-positive advanced NSCLC. Another first-line chemoimmunotherapy option backed by mature survival data. Important caveat: Exploratory PD-L1 subgroup analysis, with limited subsequent immunotherapy in the control arm. @oncoalert #LungCancer #NSCLC #Immunotherapy Full paper link in comment below ⬇️.
3
10
1
51
4,389
Ricardo Villalobos V retweeted
HOUSTON, WE HAVE A PROBLEM! 🙂 @PTarantinoMD FDA's three recent approvals based upon on PFS and ORR . Can some one explain this to me ? @OncBrothers @Timothee_MD @dr_yakupergun @HemeOncBuddy @hoperugo @DrHBurstein
8
19
2
66
14,610
Ricardo Villalobos V retweeted
Mariposa 2 Vs. HARMONi Amivantamab ( Jansen) US approved based on PFS benefit alone Interim analysis OS benefit was not there. Ivonescimab ( Summit Therapeutics) China Rejected PFS benefit alone insufficient to make regulatory approval OS benefit @ interim analysis not seen
11
23
1,781
Ricardo Villalobos V retweeted
Decades of progress. Thousands of courageous patients, families, and researchers. Progress is never just about drugs. It is about people. And our work is far from over. What comes next? @OncoAlert @OpenMedicineHQ @APCCC_Lugano #prostatecancer
🤖 Made with AI
4
42
2
97
6,429
Ricardo Villalobos V retweeted
Hallmarks of colorectal cancer subtypes👇 nature.com/articles/s41568-0… (Origins and heterogeneity of colorectal cancer)
119
2
393
23,247
Ricardo Villalobos V retweeted
First-Line Metastatic Gastric/GEJ Adenocarcinoma — ESMO 2026 Simplified! One disease. Four biomarkers. Multiple treatment options. 🔹 HER2+ → Zanidatamab + tislelizumab + chemotherapy; trastuzumab-based alternative. 🔹 MSI-H/dMMR → Immunotherapy + chemotherapy. 🔹 PD-L1+ → Nivolumab (CPS ≥5), pembrolizumab (CPS ≥1) or tislelizumab (TAP ≥5%). 🔹 CLDN18.2+ → Zolbetuximab + chemotherapy (≥75% tumour cells, IHC 2+/3+). 🔹 Biomarker-negative → Platinum–fluoropyrimidine; TFOX in selected patients. The message: Test first. Treat precisely. Biomarkers may overlap; treatment selection must be individualised. 📖 Reference: Al-Batran SE et al. ESMO Clinical Practice Guideline: Gastric and Oesophageal Cancer. Ann Oncol. 2026. DOI: 10.1016/j.annonc.2026.09.015 #ESMO2026 #GastricCancer #GEJCancer #PrecisionOncology
33
1
83
4,056
Ricardo Villalobos V retweeted
In this retrospective study of patients treated with elacestrant, those harboring ESR1 L536 mutations had a shorter time on treatment compared with patients carrying other ESR1 variants. Similarly, patients with multiple ESR1 mutations had a shorter treatment duration than those with a single mutation. aacrjournals.org/clincancerr…
1
30
1
59
4,201
Ricardo Villalobos V retweeted
Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early-Stage Breast Cancer Great review👇 ascopubs.org/doi/10.1200/JCO…
3
76
6
161
28,180
Ricardo Villalobos V retweeted
Lung Cancer-Subtypes IHC panel👇
33
92
4,508
Ricardo Villalobos V retweeted
New, large analysis of T-DXd-related ILD from 🇯🇵. Among 2801 patients, 381 (14%) developed ILD with T-DXd, of which 30 (7.9%) fatal. Most cases (83%) recovered, and steroids helped — but neither high-dose steroids nor immunosuppressants helped in G3-4 ILD. academic.oup.com/oncolo/adva…
10
47
2
164
18,721
Ricardo Villalobos V retweeted
CDK4/6 inhibitors arrest the cell cycle by activating Rb. But the authors provide compelling evidence that the story does not end there. A new Nature study shows that hypophosphorylated Rb unexpectedly enhances ER-mediated transcription. Rb relocates to enhancer regions and reactivates proliferative ER-target genes, including CCND1. So, paradoxically, CDK4/6 inhibition leads to: E2F ↓ → proliferation ↓ but at the same time Rb → ER transcription ↑ → proliferative counter-response ↑ Endocrine therapy shuts down this second pathway. This finding reveals a new mechanism that may help explain the strong biological rationale for combining CDK4/6 inhibition with endocrine therapy, while also pointing to a potential mechanism of resistance. nature.com/articles/s41586-0…
2
43
1
118
8,806
Ricardo Villalobos V retweeted
Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer Great review👇 jamanetwork.com/journals/jam…
2
36
84
6,086
Ricardo Villalobos V retweeted
📢 New ASCO Breast Cancer Surveillance Guideline Not every breast cancer survivor needs the same intensity of follow-up. Risk-stratify. De-escalate when appropriate. Intensify when risk is high. ❌ Routine tumor markers ❌ Routine metastatic imaging ❌ Routine ctDNA ✅ Appropriate mammography ✅ Selective MRI ✅ Shared decision-making Less can be more—when evidence and risk support it. #BreastCancer #ASCO #Oncology #Survivorship @drsarahsam @DFCI_BreastOnc @OncoDailyBreast
2
41
76
5,896
Ricardo Villalobos V retweeted
NCCN 2026 | Breast cancer axilla: who needs what? • cN0 → SLNB • >50, postmenopausal, cT1N0/AUS−, HR+/HER2−, G1–2 + BCS/WBRT/ET → consider NO SLNB • cN0 → SLN− → no further axillary surgery • 1–2 positive SLNs + appropriate BCS/RT → no ALND • cN+ → neoadjuvant therapy → ycN0 → SLNB/TAD • Previously positive node clipped → retrieve the clipped node • Post-NAC ypN0 → no ALND • Post-NAC ypN+ → ALND remains standard
53
2
148
8,669